Processa Pharmaceuticals, Inc. Future Amortization Expense, Year Four (Deprecated 2012-01-31)
Processa Pharmaceuticals, Inc. (PCSA) reported Future Amortization Expense, Year Four (Deprecated 2012-01-31) of $267.86 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-04-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FutureAmortizationExpenseYearFour · last filed 2015-04-14
- Processa Pharmaceuticals, Inc. future amortization expense, year four (deprecated 2012-01-31) for fiscal 2014 was $267.86K, a 25.00% decline from fiscal 2013.
- Processa Pharmaceuticals, Inc. future amortization expense, year four (deprecated 2012-01-31) for fiscal 2013 was $357.14K.
| Period end | Future Amortization Expense, Year Four (Deprecated 2012-01-31) 12 month |
|---|---|
| 2014-12-31 | $267.86K 10-K · filed 2015-04-14 |
| 2013-12-31 | $357.14K 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |